Your session is about to expire
← Back to Search
Brain Imaging + Ketamine for Suicide Risk
Study Summary
This trial is studying what happens in the brain when people have thought about or attempted suicide. It will help researchers develop better treatments for suicidal people.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious, unstable medical conditions.I do not speak English.I am between 18 and 70 years old.I am healthy without any illness that could change my brain's structure or function.I have a psychiatric disorder or a family history of suicide.I have never attempted or thought about suicide.I had a severe reaction to ketamine in a previous trial.I am part of a specific group in a Phase III trial with certain health or mental conditions.I understand the study requirements and scored at least 90% on the consent quiz.I am a healthy volunteer aged between 18 and 70.I am experiencing thoughts of suicide or have minimal symptoms of depression or anxiety.Participants need to demonstrate that they have understood the study guidelines by scoring 80% or higher on the Ketamine Response test.This exclusion applies to patients who are part of groups 1-3 and 5 in Phase I of the trial.If you are able to get pregnant, you must agree to use birth control or not have sex during the study.If you are in an active crisis, you need to agree to be admitted to the hospital.I have had thoughts about suicide or felt depressed or anxious recently.You have ongoing thoughts of hurting yourself or feeling suicidal.You need to have participated in Group 1 of Study Phase I to be eligible.I have a condition that may make ketamine treatment risky for me.I am currently in a crisis or have thoughts of suicide.I agree to be hospitalized for the study.I am between 18 and 70 years old.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can elderly citizens participate in this research?
"The age eligibility for this clinical trial is between 18 and 70 years old."
Are we enrolling new participants in this experiment at the moment?
"The study, which can be found on clinicaltrials.gov and was last edited on 11/15/2022, is recruiting patients at this time."
Which type of patient do you think would be the best candidate for this clinical trial?
"As this is a depression-focused clinical trial, all participants must have a medical diagnosis of depression. Furthermore, potential patients must be between 18 and 70 years old. Lastly, the researchers are looking for 325 individuals total."
What is the FDA's stance on Ketamine?
"There is some evidence that Ketamine is safe, but none yet to suggest that it is effective. As such, we've given it a score of 2."
How many individuals are being administered care within this trial?
"Yes, as indicated by the clinicaltrials.gov listing, this trial is actively looking for participants. Originally posted on December 1st, 2015, this study was last updated on November 15th, 2022. So far, 325 patients have been enrolled at 2 sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- National Institutes of Health Clinical Center, 9000 Rockville Pike: < 24 hours
- National Institutes of Health Clinical Center: < 48 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger